Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

Qlife: LOI (Letter of intent) with major industry player in China for Egoo Health.

Qlife's management met Hipro Biotechnology's CEO and CSO on this years AACC (Annual Scientific Meeting & Clinical Lab Expo) conference. Now they enter into LOI. Expect a signed agreement later this year.

We host CEO Thomas Warthoe next week for a closer look at the opportunities in China and the agreement with Hipro Biotechnology.

Read full announcement here: Hipro Biotechnology

Participate in next weeks event: Event 19 september 2023

Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a DigitalIR/Corporate Visibility agreement.